Virginiamycin M1
(Synonyms: 维吉尼亚霉素M1,Mikamycin A,NSC 244426,NSC 87432,Ostreogrycin A,Pristinamycin IIA,RP 12536,Streptogramin A) 目录号 : GC16050A macrolide antibiotic
Cas No.:21411-53-0
Sample solution is provided at 25 µL, 10mM.
Virginiamycin M1 is a macrolide antibiotic that reversibly inhibits protein synthesis [1][2][3].
Virginiamycin complex contains two antibiotics, virginiamycin M1 and virginiamycin S1. Streptogramins are divided into class A and class B based on their structures. Virginiamycin M1, also known as Streptogramin A, is a member of the streptogramin A group of antibiotics, which bind the 50S ribosomal subunit at the peptidyl transferase center to inhibit initiation and translocation. They show good bactericidal activity against methicillin-resistant S. aureus (MRSA), although resistance in MRSA is conferred by the cfr gene. Virginiamycin M1 has activity against gram-positive and in select cases gram-negative bacteria. Combination of group A and B streptogramins exhibit bactericidal activity [1]. Virginiamycin M1 acted synergistically with virginiamycin S1 to irreversibly inhibit protein synthesis in bacteria. In cell-free systems, Virginiamycin M1 and virginiamycin S1 bound to the large ribosomal subunit, and the affinity of ribosomes for VS is increased by VM [2][3].
References:
[1]. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014 Aug 28;6:25-64.
[2]. Kehrenberg C, Cuny C, Strommenger B, et al. Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr. Antimicrob Agents Chemother. 2009 Feb;53(2):779-81.
[3]. Parfait R, Cocito C. Lasting damage to bacterial ribosomes by reversibly bound virginiamycin M. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5492-6.
Cas No. | 21411-53-0 | SDF | |
别名 | 维吉尼亚霉素M1,Mikamycin A,NSC 244426,NSC 87432,Ostreogrycin A,Pristinamycin IIA,RP 12536,Streptogramin A | ||
化学名 | (3R,4R,5E,10E,12E,14S)-8,9,14,15,24,25-hexahydro-14-hydroxy-4,12-3H-21,18-nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone | ||
Canonical SMILES | O=C(/C=C/[C@@H](C)[C@@H](C(C)C)OC(C1=CCCN1C(C2=COC(C3)=N2)=O)=O)NC/C=C\C(C)=C\[C@@H](O)CC3=O | ||
分子式 | C28H35N3O7 | 分子量 | 525.6 |
溶解度 | DMSO : 100 mg/mL (190.26 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.9026 mL | 9.5129 mL | 19.0259 mL |
5 mM | 0.3805 mL | 1.9026 mL | 3.8052 mL |
10 mM | 0.1903 mL | 0.9513 mL | 1.9026 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet